GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (HKSE:06996) » Definitions » Debt-to-EBITDA

Antengene (HKSE:06996) Debt-to-EBITDA : -0.29 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Antengene Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Antengene's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$7.95 Mil. Antengene's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$211.93 Mil. Antengene's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$-761.51 Mil. Antengene's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.29.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Antengene's Debt-to-EBITDA or its related term are showing as below:

HKSE:06996' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.37   Med: -0.06   Max: 0
Current: -0.37

HKSE:06996's Debt-to-EBITDA is ranked worse than
100% of 270 companies
in the Biotechnology industry
Industry Median: 1.31 vs HKSE:06996: -0.37

Antengene Debt-to-EBITDA Historical Data

The historical data trend for Antengene's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antengene Debt-to-EBITDA Chart

Antengene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial -0.01 - -0.02 -0.10 -0.37

Antengene Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.02 -0.13 -0.07 -0.32 -0.29

Competitive Comparison of Antengene's Debt-to-EBITDA

For the Biotechnology subindustry, Antengene's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antengene's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antengene's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Antengene's Debt-to-EBITDA falls into.



Antengene Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Antengene's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(7.946 + 211.925) / -601.919
=-0.37

Antengene's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(7.946 + 211.925) / -761.508
=-0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Antengene  (HKSE:06996) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Antengene Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Antengene's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Antengene (HKSE:06996) Business Description

Traded in Other Exchanges
N/A
Address
1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in China and other regions.
Executives
Jay Mei 2023 Grat 2201 Interest of corporation controlled by you
Mei Jay 2201 Interest of corporation controlled by you
Begonia Investment Ltd. 2101 Beneficial owner
Qiming Corporate Gp V, Ltd.
The Core Trust Company Limited 2301 Trustee
Tct (bvi) Limited 2501 Other
Fountainvest China Capital Partners Gp3 Ltd. 2201 Interest of corporation controlled by you
Fountainvest China Capital Partners Fund Iii, L.p. 2201 Interest of corporation controlled by you
Fmr Llc 2201 Interest of corporation controlled by you
Fidelity Investment Trust 2101 Beneficial owner
Jay Mei 2020 Grat 2201 Interest of corporation controlled by you
Meiland Pharma Tech Spc
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd
Boyu Capital General Partner Iii, L.p.

Antengene (HKSE:06996) Headlines

No Headlines